Corrigendum to "Effects of raloxifene on cognition in postmenopausal women with schizophrenia: Adouble-blind, randomized, placebo-controlled trial" [Eur. Neuropsychopharmacol. 24, (2014), 223-231] Doi 10.1016/j.euroneuro.2013.11.012;Effects of raloxifene on cognition in postmenopausal women with schizophrenia: A double-blind, randomized, placebo-controlled trial

European Neuropsychopharmacology

Volumn 24, Issue 2, 2014, Pages 223-231

  Huerta Ramos, Elena ^a,b,c   Iniesta, Raquel ^a,b,c   Ochoa, Susana ^a,c   Cobo, Jesús ^d   Miquel, Eva ^a   Roca, Mercedes ^a,c   Serrano Blanco, Antoni ^a,c   Teba, Fernando ^a   Usall, Judith ^a,b,c  

^a PARC SANITARI SANT JOAN DE DÉU   (Spain)

^b Fundacio Hospital Sant Joan de Déu   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Hospital Universitari Parc Taulí   (Spain)

Author keywords

Cognitive function; Postmenopausal women; Raloxifene; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; ESTROGEN; RALOXIFENE;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ARTICLE; ATTENTION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXECUTIVE FUNCTION; FEMALE; HUMAN; MEMORY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

COGNITIVE FUNCTION; POSTMENOPAUSAL WOMEN; RALOXIFENE; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; ATTENTION; DOUBLE-BLIND METHOD; EXECUTIVE FUNCTION; FEMALE; HUMANS; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSTMENOPAUSE; RALOXIFENE; SCHIZOPHRENIA; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SOCIOECONOMIC FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893640658     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.05.001     Document Type: Erratum

References (52)

1. Audesirk T., Cabell L., Kern M., Audesirk G. Beta-estradiol influences differentiation of hippocampal neurons in vitro through an estrogen receptor-mediated process. Neuroscience 2003, 121:927-934.
2. Bender R., Lange S. Adjusting for multiple testing-when and how?. J. Clin. Epidemiol. 2001, 54:343-349.
3. Benedet M.J., Alexandre M.A. Test de Aprendizaje Verbal España-Complutense (TAVEC) 1998, TEA Ediciones, Madrid.
4. Bergemann N., Parzer P., Jaggy S., Auler B., Mundt C., Maier-Braunleder S. Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial. Schizophr. Bull. 2008, 34:1172-1181.
5. Ciriza I., Carrero P., Azcoitia I., Lundeen S.G., Garcia-Segura L.M. Selective estrogen receptor modulators protect hippocampal neurons from kainic acid excitotoxicity: differences with the effect of estradiol. J. Neurobiol. 2004, 61:209-221.
6. Conners C.K. Conners' Continuous Performance Test CPT-II. Technical Guide and Software Manual 2002, Multi Health Systems, North Tonawanda, NY.
7. DonCarlos L.L., Azcoitia I., Garcia-Segura L.M. Neuroprotective actions of selective estrogen receptor modulators. Psychoneuroendocrinology 2009, 34(1):S113-22.
8. Eichenbaum H. The hippocampus and declarative memory: cognitive mechanisms and neural codes. Behav. Brain Res. 2001, 127:199-207.
9. Elvevag B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 2000, 14:1-21.
10. Fioravanti M., Bianchi V., Cinti M.E. Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. BMC Psychiatry 2012, 12:64-244X-12-64.
11. Fisher L.M., Freed D.M., Corkin S. Stroop color-word test performance in patients with Alzheimer's disease. J. Clin. Exp. Neuropsychol. 1990, 12:745-758.
12. Fletcher P.C., Henson R.N. Frontal lobes and human memory: insights from functional neuroimaging. Brain 2001, 124:849-881.
13. Fletcher P.C., Shallice T., Dolan R.J. The functional roles of prefrontal cortex in episodic memory. I. Encoding. Brain 1998, 121(Pt 7):1239-1248.
14. Godsland I.F. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil. Steril. 2001, 75:898-915.
15. Goekoop R., Barkhof F., Duschek E.J., Netelenbos C., Knol D.L., Scheltens P., Rombouts S.A. Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI study in healthy elderly males. Neuropsychopharmacology 2006, 31:1508-1518.
16. Gorenstein C., Rennó J., Vieira Filho A.H., Gianfaldoni A., Gonçalves M.A., Halbe H.W., Fernandes C.E., Demétrio F.N. Estrogen replacement therapy and cognitive functions in healthy postmenopausal women: a randomized trial. Arch. Womens Ment. Health 2011, 14(5):367-373.
17. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003, 28(2):17-54.
18. Hafner H., Behrens S., De Vry J., Gattaz W.F. An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia. Psychiatry Res. 1991, 38:125-134.
19. Harvey P.D., Koren D., Reichenberg A., Bowie C.R. Negative symptoms and cognitive deficits: what is the nature of their relationship?. Schizophr. Bull. 2006, 32:250-258.
20. Haskell S.G., Richardson E.D. The effect of raloxifene on cognitive function in postmenopausal women: a randomized clinical trial. Conn. Med. 2004, 68:355-358.
21. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12:426-445.
22. Jacobsen D.E., Samson M.M., Emmelot-Vonk M.H., Verhaar H.J. Raloxifene improves verbal memory in late postmenopausal women: a randomized, double-blind, placebo-controlled trial. Menopause 2010, 17:309-314.
23. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
24. Klatzky R.L. Human Memory 1982, W.H. Freeman, San Francisco.
25. Kremen W.S., Seidman L.J., Faraone S.V., Toomey R., Tsuang M.T. The paradox of normal neuropsychological function in schizophrenia. J. Abnorm. Psychol. 2000, 109:743-752.
26. Kulkarni J., Gurvich C., Gilbert H., Mehmedbegovic F., Mu L., Marston N., Gavrilidis E., de Castella A. Hormone modulation: a novel therapeutic approach for women with severe mental illness. Aust. N. Z. J. Psychiatry 2008, 42:83-88.
27. Kulkarni J., Gurvich C., Lee S.J., Gilbert H., Gavrilidis E., de Castella A., Berk M., Dodd S., Fitzgerald P.B., Davis S.R. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010, 35:1142-1147.
28. Legault C., Maki P.M., Resnick S.M., Coker L., Hogan P., Bevers T.B., Shumaker S.A. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J. Clin. Oncol. 2009, 27:5144-5152.
29. Lezak M.D. Neuropsychological Assessment 1995, Oxford University Press, New York.
30. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. 1987, 334:1-100.
31. Moscovitch M., Umiltà C. Modularity and neuropsychology: implications for the organization of attention and memory in normal and brain-damaged people. Modular Deficits in Alzheimertype Dementia 1990, MIT Press, Cambridge. M.F. Schwartz (Ed.).
32. Moses E.L., Drevets W.C., Smith G., Mathis C.A., Kalro B.N., Butters M.A., Leondires M.P., Greer P.J., Lopresti B., Loucks T.L., Berga S.L. Effects of estradiol and progesterone administration on human serotonin: 2 A receptor binding: a PET study. Biol. Psychiatry 2000, 48:854-860.
33. Neele S.J., Rombouts S.A., Bierlaagh M.A., Barkhof F., Scheltens P., Netelenbos J.C. Raloxifene affects brain activation patterns in postmenopausal women during visual encoding. J. Clin. Endocrinol. Metab. 2001, 86:1422-1424.
34. Ochoa S., Usall J., Cobo J., Labad X., Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr. Res. Treat. 2012, 2012:916198.
35. Reeve W.V., Schandler S.L. Frontal lobe functioning in adolescents with attention deficit hyperactivity disorder. Adolescence 2001, 36:749-765.
36. Reitan R., Wolfson D. Category test and trail making test as measures of frontal lobe functions. Clin. Neuropsychol. 1995, 9:50-56.
37. Riecher-Rossler A., Kulkarni J. Estrogens and gonadal function in schizophrenia and related psychoses. Curr. Top. Behav. Neurosci. 2011, 8:155-171.
38. Riecher-Rossler A., Hafner H., Stumbaum M., Maurer K., Schmidt R. Can estradiol modulate schizophrenic symptomatology?. Schizophr. Bull. 1994, 20:203-214.
39. Saitta A., Altavilla D., Cucinotta D., Morabito N., Frisina N., Corrado F., D'Anna R., Lasco A., Squadrito G., Gaudio A., Cancellieri F., Arcoraci V., Squadrito F. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1512-1519.
40. Seeman M.V.L.M. The role of estrogens in schizophrenia gender differences. Schizophr. Bull. 1990, 16:185-194.
41. Seisdedos N., Corral S., Cordero A., de la Cruz M.V., Hernández M.V., Pereña J. WAIS III. Manual Técnico 1999, TEA ediciones, Madrid.
42. Steinberg K.K., Thacker S.B., Smith S.J., Stroup D.F., Zack M.M., Flanders W.D., Berkelman R.L. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. J. Am. Med. Assoc. 1991, 265:1985-1990.
43. Strauss E., Sherman E.M.S., Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary 2006, Oxford University Press, NY. third ed.
44. Stroop J.R. Studies of interference in serial verbal reactions. J. Exp. Psychol. 1935, 18(6):643-662.
45. Stuss D.T., Alexander M.P., Hamer L., Palumbo C., Dempster R., Binns M., Levine B., Izukawa D. The effects of focal anterior and posterior brain lesions on verbal fluency. J. Int. Neuropsychol. Soc. 1998, 4:265-278.
46. Terauchi M., Obayashi S., Akiyoshi M., Kato K., Matsushima E., Kubota T. Effects of oral estrogen and hypnotics on Japanese peri- and postmenopausal women with sleep disturbance. J. Obstet. Gynaecol. Res. 2011, 37:741-749.
47. Ucok A., Cakir S., Duman Z.C., Discigil A., Kandemir P., Atli H. Cognitive predictors of skill acquisition on social problem solving in patients with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2006, 256:388-394.
48. Usall J., Huerta-Ramos E., Iniesta R., Cobo J., Araya S., Roca M., Serrano-Blanco A., Teba F., Ochoa S. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J. Clin. Psychiatry 2011, 72:1552-1557.
49. Velazquez-Zamora D.A., Garcia-Segura L.M., Gonzalez-Burgos I. Effects of selective estrogen receptor modulators on allocentric working memory performance and on dendritic spines in medial prefrontal cortex pyramidal neurons of ovariectomized rats. Horm. Behav. 2012, 61:512-517.
50. Wharton W., Baker L.D., Gleason C.E., Dowling M., Barnet J.H., Johnson S., Carlsson C., Craft S., Asthana S. Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial. J. Alzheimers Dis. 2011, 26(3):495-505.
51. Yaffe K., Krueger K., Sarkar S., Grady D., Barrett-Connor E., Cox D.A., Nickelsen T. Cognitive function in postmenopausal women treated with raloxifene. N. Engl. J. Med. 2001, 344:1207-1213. Multiple Outcomes of Raloxifene Evaluation Investigators.
52. Zec R.F., Trivedi M.A. The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review. Neuropsychol. Rev. 2002, 12:65-109.